Astigmatism

STAAR Surgical to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, March 6, 2024

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors at the following conferences:

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors at the following conferences:
    Oppenheimer Healthcare MedTech & Services Conference, Tuesday, March 12
    Management will also meet with investors in Shenzhen and Shanghai, China, from Monday, March 18 through Wednesday, March 20.
  • Investor participation is by invitation from each sponsoring brokerage firm.

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Monday, February 26, 2024

Gross profit margin for the fourth quarter of 2023 was 79.6% of total net sales compared to the prior year quarter of 77.7% of total net sales.

Key Points: 
  • Gross profit margin for the fourth quarter of 2023 was 79.6% of total net sales compared to the prior year quarter of 77.7% of total net sales.
  • Product mix favorably impacted gross margin in the fourth quarter of 2023 as compared to the prior year quarter.
  • Operating expenses for the fourth quarter of 2023 were $50.3 million compared to the prior year quarter of $48.8 million.
  • Operating income for the fourth quarter of 2023 was $10.4 million or 13.7% of net sales as compared to $1.0 million or 1.5% of net sales for the fourth quarter of 2022.

New Swiss Made Features for Cataract Surgery Lens Selection

Retrieved on: 
Thursday, February 22, 2024

The company Swiss Advanced Vision (SAV-IOL SA) has announced the launch of New Features for its Toric Calculator improving the overall calculation experience.

Key Points: 
  • The company Swiss Advanced Vision (SAV-IOL SA) has announced the launch of New Features for its Toric Calculator improving the overall calculation experience.
  • View the full release here: https://www.businesswire.com/news/home/20240222791326/en/
    Launch of New Features, discover the unique Incision Location Optimization tool on SAV-IOL Toric Calculator.
  • Since 2009, the Swiss company has been developing advanced IOLs with the goal to restore the missing accommodation left by the removal of the natural lens.
  • Swiss Advanced Vision will keep the pace of innovative product development and is already working on new functionalities for their users, stay tuned!

STAAR Surgical to Report Fourth Quarter Results on February 26, 2024

Retrieved on: 
Monday, February 19, 2024

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close.
  • STAAR will host a conference call and webcast on Monday, February 26 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call please dial 877-270-2148 for domestic participants and 412-902-6510 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .

Dr. Kent Wellish Successfully Implants First Bausch + Lomb Toric Aspire "Range of Vision" IOL in Las Vegas

Retrieved on: 
Thursday, March 7, 2024

PHOENIX, March 7, 2024 /PRNewswire-PRWeb/ -- Dr. Kent Wellish of Wellish Vision Institute, an affiliate of American Vision Partners, has achieved a significant milestone in the field of ophthalmology by successfully implanting the first Bausch + Lomb Toric Aspire "Range of Vision" intraocular lens (IOL) in Las Vegas. This innovative lens offers patients with cataracts the potential for improved vision at various distances.

Key Points: 
  • Dr. Kent Wellish of Wellish Vision Institute, an affiliate of American Vision Partners, has achieved a significant milestone in the field of ophthalmology by successfully implanting the first Bausch + Lomb Toric Aspire "Range of Vision" intraocular lens (IOL) in Las Vegas.
  • PHOENIX, March 7, 2024 /PRNewswire-PRWeb/ -- Dr. Kent Wellish of Wellish Vision Institute, an affiliate of American Vision Partners, has achieved a significant milestone in the field of ophthalmology by successfully implanting the first Bausch + Lomb Toric Aspire "Range of Vision" intraocular lens (IOL) in Las Vegas.
  • The Bausch + Lomb Toric Aspire "Range of Vision" IOL, recently launched as Envista Aspire is designed to provide an extended range of vision, including intermediate vision, reducing the need for glasses for activities such as reading, computer use, and driving.
  • Visit https://ir.bausch.com/ for more information about the Bausch + Lomb Toric Aspire "Range of Vision" IOL.

The Waring Vision Institute's Dr. George Waring IV will be the First in the Nation to Introduce TENEO™ Technology to Patients

Retrieved on: 
Thursday, February 8, 2024

CHARLESTON, S.C., Feb. 8, 2024 /PRNewswire/ -- Dr. George Waring IV of The Waring Vision Institute (Mt. Pleasant, SC ) will be the first in the nation to perform patient treatments on the just approved TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism. "The precise engineering of this platform delivers a fast, small, technologically advanced machine that provides an exceptional experience for both surgeons and patients," said Luc Bonnefoy, president, Global Surgical, Bausch + Lomb. He added, "We are excited to partner with Dr. Waring and the professionals at the Waring Vision Institute to launch this important vision enhancement technology in the U.S."

Key Points: 
  • Pleasant, SC ) will be the first in the nation to perform patient treatments on the just approved TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism.
  • "The precise engineering of this platform delivers a fast, small, technologically advanced machine that provides an exceptional experience for both surgeons and patients," said Luc Bonnefoy, president, Global Surgical, Bausch + Lomb.
  • He added, "We are excited to partner with Dr. Waring and the professionals at the Waring Vision Institute to launch this important vision enhancement technology in the U.S."
    "FDA approval of TENEO represents a major milestone for the advancement of laser vision correction technology," said George Waring IV, M.D., ophthalmologist, founder and medical director, Waring Vision Institute.
  • Dr. George Waring IV is Founder and Medical Director of the Waring Vision Institute , South Carolina.

SIFI ANNOUNCES THE ESTABLISHMENT OF A JOINT VENTURE IN THE UNITED ARAB EMIRATES

Retrieved on: 
Monday, February 5, 2024

The JV will have exclusive rights to SIFI's range of IOLs, including the innovative Extended Depth of Focus ("EDOF") IOLs.

Key Points: 
  • The JV will have exclusive rights to SIFI's range of IOLs, including the innovative Extended Depth of Focus ("EDOF") IOLs.
  • The JV will be based in Dubai and initially focus on the United Arab Emirates ("UAE"), expanding its commercial reach to Bahrein, Oman, Qatar, Kuwait, and the Kingdom of Saudi Arabia as a second step.
  • Approximately 100.000 cataract surgeries are performed each year across these Countries with an annual growth rate of 3.0%, with almost 50% Premium IOLs.
  • "It is therefore a great honor to invest alongside SIFI and bring such innovation to ophthalmologists and patients".

SIFI ANNOUNCES THE ESTABLISHMENT OF A JOINT VENTURE IN THE UNITED ARAB EMIRATES

Retrieved on: 
Monday, February 5, 2024

The JV will have exclusive rights to SIFI's range of IOLs, including the innovative Extended Depth of Focus ("EDOF") IOLs.

Key Points: 
  • The JV will have exclusive rights to SIFI's range of IOLs, including the innovative Extended Depth of Focus ("EDOF") IOLs.
  • The JV will be based in Dubai and initially focus on the United Arab Emirates ("UAE"), expanding its commercial reach to Bahrein, Oman, Qatar, Kuwait, and the Kingdom of Saudi Arabia as a second step.
  • Approximately 100.000 cataract surgeries are performed each year across these Countries with an annual growth rate of 3.0%, with almost 50% Premium IOLs.
  • "It is therefore a great honor to invest alongside SIFI and bring such innovation to ophthalmologists and patients".

STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision

Retrieved on: 
Tuesday, January 23, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240123947715/en/
    STAAR Surgical and SharpeVision will collaborate on marketing and education activities to elevate awareness of EVO ICL and significantly increase availability of the lenses to all qualified patients in SharpeVision clinics.
  • STAAR Surgical will also provide additional practice development and clinical support.
  • “We are pleased to announce SharpeVision as a new partner under our U.S. Highway 93 go-to-market program initiated in October 2023.
  • Naves, J. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery.

EQS-News: U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Retrieved on: 
Saturday, January 13, 2024

The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.

Key Points: 
  • The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.
  • ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
  • With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
  • For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .